
Company valuation, historical trends, and peer comparisons.
According to Ligand Pharmaceuticals Incorporated’s latest financial reports and current stock price. The company's current Enterprise Value is 7.40B. This represents a change of 33.87% compared to the average of 5.53B of the last 4 quarters.
The mean historical Enterprise Value of Ligand Pharmaceuticals Incorporated over the last ten years is 1.85B. The current 7.40B Enterprise Value has changed 299.69% with respect to the historical average. Over the past ten years (40 quarters), LGND's Enterprise Value was at its highest in in the September 2026 quarter at 7.33B. The Enterprise Value was at its lowest in in the September 2019 quarter at 708.32M.
Average
1.85B
Median
1.82B
Minimum
1.17B
Maximum
3.93B
Discovering the peaks and valleys of Ligand Pharmaceuticals Incorporated Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 107.58%
Maximum Annual Enterprise Value = 3.93B
Minimum Annual Increase = -38.68%
Minimum Annual Enterprise Value = 1.17B
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 3.93B | 107.58% |
| 2024 | 1.89B | 55.47% |
| 2023 | 1.22B | 4.20% |
| 2022 | 1.17B | -38.68% |
| 2021 | 1.91B | 34.99% |
| 2020 | 1.41B | -22.13% |
| 2019 | 1.81B | -7.12% |
| 2018 | 1.95B | 7.37% |
| 2017 | 1.82B | 30.67% |
| 2016 | 1.39B | 3.62% |
The current Enterprise Value of Ligand Pharmaceuticals Incorporated (LGND) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
2.35B
5-year avg
2.02B
10-year avg
1.85B
Ligand Pharmaceuticals Incorporated’s Enterprise Value is less than Genmab A/S (36.89B), less than Incyte Corporation (21.80B), less than Exelixis, Inc. (18.14B), greater than Rigel Pharmaceuticals, Inc. (937.22M), greater than BioCryst Pharmaceuticals, Inc. (2.10B), less than Amgen Inc. (299.50B), less than Pfizer Inc. (236.34B), less than Bristol-Myers Squibb Company (166.45B), less than AbbVie Inc. (591.13B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 36.89B | $33.89B | |
| 21.80B | $25.04B | |
| 18.14B | $18.29B | |
| 937.22M | $958.09M | |
| 2.10B | $2.11B | |
| 299.50B | $258.68B | |
| 236.34B | $175.49B | |
| 166.45B | $131.21B | |
| 591.13B | $521.00B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ligand Pharmaceuticals Incorporated using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ligand Pharmaceuticals Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Ligand Pharmaceuticals Incorporated's Enterprise Value?
What is the highest Enterprise Value for Ligand Pharmaceuticals Incorporated (LGND)?
What is the 3-year average Enterprise Value for Ligand Pharmaceuticals Incorporated (LGND)?
What is the 5-year average Enterprise Value for Ligand Pharmaceuticals Incorporated (LGND)?
How does the current Enterprise Value for Ligand Pharmaceuticals Incorporated (LGND) compare to its historical average?